Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples